NewsPeople

Supriya Lifescience appoints Rajeev Kumar Jain as CEO

He has over 35+ years of rich functional experience in the manufacturing domain of bulk drugs, intermediate and API

Supriya Lifescience has announced the appointment of Rajeev Kumar Jain as Chief Executive Officer (CEO) & Key Managerial Personnel (KMP) w.e.f. October 3, 2022.

Jain is a Master of Business Administration (Marketing) from Jivaji University, Gwalior and BSc (PCB). Additionally, he has taken part in business seminars and workshops on corporate transformation in China, Germany, and the Netherlands.

He has over 35+ years of rich functional experience in the manufacturing domain of bulk drugs, intermediate and API with a “Safety First, Quality Must and EBIDTA Growth” mindset. He is experienced in managing regulations and guidelines, such as those from the US FDA, KFDA, EMA, ANVISA, CDSCO, ISO, PMDA, and IDL CHINA.

Throughout his career, he has maintained an impeccable record with reputable companies like Morepen Labs Ltd., Ind Swift Labs, Arch Pharma, Trident Group, Max India (DSM), etc.

“I am excited to be joining the Supriya team,” said Jain. “I believe Supriya has a great business model and talented management team that uniquely positions it to capitalise on the changing pharmaceutical environment. As the industry evolves, I believe Supriya is in a position to reach newer heights with backward integration, focus on R&D, increase capacity, and capitalising on CMO/CDMO potential. We would endeavour to achieve healthy revenue growth with healthy margins and upgrade to the evolving GMP and EHS standards.”

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close